


Evolution of Small Molecule Kinase Drugs

Helen Lightfoot,[†] Frederick Goldberg,^{††} Joerg Sedelmeier[‡]



The poster depicts INN drug names, INN registration dates, classification by relevant biological targets and highlights structural similarities within the respective groups. * Reduced selectivity; ** Highly promiscuous kinase inhibitors.

[†]GDD/TRD/Chemical & Analytical Development, Novartis Pharma, Basel, Switzerland; ^{††}Hit Discovery, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Alderley Park, UK; [‡]Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.